S300: HEALTH-RELATED QUALITY OF LIFE IN TRANSPLANT-INELIGIBLE REAL-LIFE MULTIPLE MYELOMA PATIENTS TREATED WITH BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS. LENALIDOMIDE-DEXAMETHASONE (RD). (23rd June 2022) - D'Agostino, M.; Bringhen, S.; Ria, R.; Ciceri, F.; Falcone, A. P.; Michieli, M.; Grasso, M.; Pane, F.; Quaresima, M.; Cattel, F.; Mirabile, M.; Fioritoni, F.; et al.